CDEK by Data4ThePeople
Sign in Sign up
← All drugs Report issue

Atosiban

Trade name: tractocile

Small moleculeexperimental

Atosiban, sold under the brand name Tractocile among others, is an inhibitor of the hormones oxytocin and vasopressin. It is used as an intravenous medication as a labour repressant (tocolytic) to halt premature labor. It was developed by Ferring Pharmaceuticals in Sweden and first reported in the literature in 1985. Originally marketed by Ferring Pharmaceuticals, it is licensed in proprietary and generic forms for the delay of imminent preterm birth in pregnant adult women. — Wikipedia

Clinical trial activity

23 trials · 56 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
8
Phase 3
4
Phase 4
4

Earliest trial started Apr 1, 2007 (NCT01429545)

Timeline

2000s

  1. Jan 1, 2007

    Earliest Phase 2 Sponsor(trial)

  2. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Studied for

Mechanism of action

  • Oxytocin receptorANTAGONIST

    OXTR antagonist

    Atosiban is a synthetic peptide which acts as a competitive antagonist of oxytocin (and vasopressin) at human uterine oxytocin receptors. Atosiban inhibits the oxytocin-mediated release of inositol trisphosphate from the myometrial cell membrane. As a result, there is reduced release of intracellular, stored calcium from the sarcoplasmic reticulum of myometrial cells, and reduced influx of Ca2+ from the extracellular space through voltage gated channels. As a result there is a rapid inhibition of uterine contractility. In addition, atosiban suppresses oxytocin-mediated release of prostaglandin E and F from the decidua.

Chemistry & pharmacology

Loading structure…

SMILES

CCOc1ccc(C[C@H]2NC(=O)CCSSC[C@@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H]([C@@H](C)CC)NC2=O)cc1
Mol. weight
994.21 g/mol
Lipinski Ro5
3 violation(s)
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No
Delivery
Parenteral

Oral

No

Parenteral

Yes

Topical

No

Sources

Also known as

  • 1-deamino-2-tyr(oet)-4-thr-8-orn-oxytocin
  • antocin
  • antocin ii
  • atosiban
  • atosiban
  • atosiban
  • atosiban
  • atosiban
  • atosiban
  • atosiban acetate
  • atosiban acetate
  • atosiban acetate
  • atosiban acetate
  • atosiban acetate
  • (mpa(1)-d-tyr(et)(2)-thr(4)-orn(8))-oxytocin
  • (mpa(1),d-tyr(et)2,thr(4),orn(8))oxytocin
  • orf 22164
  • orf-22164
  • orf-22164
  • orf-22164
  • oxytocin, 1-deamino-o-ethyltyrosyl(2)-threonyl(4)-ornithine(8)-
  • oxytocin, 1-deamino-(o-et-tyr)(2)-thr(4)-orn(8)-
  • rwj 22164
  • rwj-22164
  • rwj-22164
  • rwj-22164
  • tractocil
  • tractocile
  • tractocile
  • tractocile

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT07185230N/AOct 1, 2025Jiao Tong University
NCT07140237Early Phase 1 (Phase 1)Sep 30, 2025University of Electronic Science and Technology of China
NCT07093060Early Phase 1 (Phase 1)Jun 9, 2025University of Electronic Science and Technology of China
NCT05382143Phase 2Feb 1, 2022Radboud University
NCT03904745N/AMar 31, 2019Bezmialem University, Yeditepe University
NCT03369262Phase 2Jan 10, 2018ObsEva SA
NCT06399965N/AJan 3, 2018Chongqing Medical University
NCT06537778N/AJan 3, 2018Chongqing Medical University
NCT05693688Phase 4Dec 1, 2017Amphia Hospital Breda, the Netherlands, Deventer Ziekenhuis, Erasmus University Rotterdam, Flevoziekenhuis, Franciscus Gasthuis, Gelre Hospitals, Groene Hart Ziekenhuis, Isala Clinics, Zwolle, The Netherlands, Leiden University, Maastricht University, Medical Center Haaglanden, Medical Center Leeuwarden, Medisch Spectrum Twente, National Maternity Hospital, Ireland, OLVG hospital, Amsterdam, Radboud University, Rijnstate Hospital, Spaarne Gasthuis, St. Antonius Hospital, Nieuwegein, Tergooi Hospital, University of Amsterdam, University of Groningen, University of Nottingham, University of Twente, Utrecht University, ZonMw: The Netherlands Organisation for Health Research and Development, Zuyderland Medisch Centrum
NCT04468568N/AJan 8, 2017University of Sao Paulo
NCT02893722Phase 1Jan 1, 2017Jiao Tong University
NCT02725736Phase 3Mar 1, 2016Tel Aviv University
NCT02292784Phase 3Jun 1, 2015GlaxoSmithKline, PPD
NCT02292771Phase 3Mar 1, 2015GlaxoSmithKline, PPD
NCT03570294N/AFeb 1, 2014Polish Mother Memorial Hospital Research Institute
NCT01673399Phase 4Feb 1, 2012AZ Jan Palfijn Gent, Onze Lieve Vrouw Hospital
NCT01501214Phase 4Dec 1, 2011Southern Medical University, The University of Hong Kong, Vietnam National University
NCT01314859Phase 3Jul 1, 2011Complexo Hospitalario Arquitecto Marcide, Complexo Hospitalario de Ourense, Complexo Hospitalario de Pontevedra, Hospital Universitari Son Dureta, University of Coruna, University of Santiago
NCT01493440N/AMar 1, 2011An Sinh Hospital, Ho Chi Minh City University of Medicine and Pharmacy, Vietnam National University
NCT00679705Phase 1May 1, 2008Ghent University
Showing 20 of 23 trials
Page 1 / 2

Organizations

Research & Development (56)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Chongqing Medical UniversityAcademic/Hospital2212018
GlaxoSmithKlineFor profit2212015
Jiao Tong UniversityAcademic/Hospital2222017
PPDFor profit2012015
Radboud UniversityAcademic/Hospital2122017
University of Electronic Science and Technology of ChinaAcademic/Hospital2212025
Vietnam National UniversityAcademic/Hospital2022011
Amphia Hospital Breda, the NetherlandsAcademic/Hospital1012017
An Sinh HospitalAcademic/Hospital1112011
AZ Jan Palfijn GentAcademic/Hospital1112012
Bezmialem UniversityAcademic/Hospital1112019
Complexo Hospitalario Arquitecto MarcideAcademic/Hospital1012011
Complexo Hospitalario de OurenseAcademic/Hospital1012011
Complexo Hospitalario de PontevedraAcademic/Hospital1012011
Deventer ZiekenhuisAcademic/Hospital1012017
Emek Medical CenterAcademic/Hospital1012008
Erasmus University RotterdamAcademic/Hospital1012017
FerringFor profit1112007
FlevoziekenhuisAcademic/Hospital1012017
Franciscus GasthuisAcademic/Hospital1012017
56 organizations
Page 1 / 3